Table 6.

Clinical trials using G-CSF injection

Author [ref.]	Sample size	Clinical scenario	G-CSF dose (μg/kg/day)	Route of administration	Duration of G-CSF therapy (days)	Peak WBC count (×103/μl)
Engelmann et al. [2]	23	AMI	10	s.c.	5	42.9 ± 25.7
Ince et al. [5]	15	AMI	10	s.c.	6	55 ± 8
Nefussy et al. [12]	19	ALS	5	s.c.	4	30.0 ± 7.2
Ripa et al. [15]	39	AMI	10	s.c.	6	51 ± 8
Shyu et al. [21]	7	CI	15	s.c.	5	42.9 ± 9.6
Takano et al. [22]	18	AMI	2.5	s.c.	5	29.4 ± 9
Valgimigli et al. [23]	10	AMI	5	s.c.	4	35 ± 11
Zohlnhofer et al. [27]	56	AMI	10	s.c.	5	48 ± 15
Our cases	5	Myelopathy	5	i.v.	5	26.7 ± 10.7
	10	Myelopathy	10	i.v.	5	35.2 ± 7.2

CI cerebral infarction, AMI acute myocardial infarction, ALS amyotrophic lateral sclerosis, s.c. subcutaneous injection, i.v. intravenous injection